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Background. Cardiovascular diseases (CVD) are the most prevalent cause of death from 
disease and disability in the world. Reliable markers are needed to assess and reduce 
cardiovascular risk. The aim of this study was to determine if insulin resistance indexes, 
triglycerides to HDL-cholesterol ratio (TG/HDL-c) and triglycerides to glucose index (TGI), are 
biomarkers for lifetime cardiovascular risk. Methods. This analytical cross-sectional study was 
performed in health workers from the Hospital de Huaycan in Peru. The QRISK model was used 
to measure lifetime cardiovascular risk. The association and diagnostic accuracy for insulin 
resistance indexes were determined using Poisson regression models and ROC curves with 
Youden index, respectively. Results. In total 291 adults (207 women and 84 men) were 
analyzed. In the multivariable analysis the 3rd tertil of TG/HDL-c (PRa:2.72, CI95% 1.13 - 6.57) 
and TGI (PRa:4.73, CI95% 1.56 - 14.31) increased significantly the lifetime cardiovascular risk 
compared to their 1st tertil. The cut-off values of TG/HDL-c was 2.64 (AUC:0.77), 3.90 
(AUC:0.80) and 2.64 (AUC:0.74) for the overall population, men and women, respectively. 
Likewise, the cut-off values of TGI was 9.04 (AUC:0.80), 8.95 (AUC:0.79) and 9.04 (AUC:0.80) 
for the overall population, men and women, respectively. Conclusion. TG/HDL-c and TGI 
presented significant association with lifetime cardiovascular risk. However, TGI presented a 
stronger association than TG/HDL-c. Both TG/HDL-c and TGI are shown to be reliable markers 
for cardiovascular risk in adults. 
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Introduction 
Cardiovascular diseases (CVD) are the leading cause of death, disability and also a major public 
health problem worldwide. [1–3] The World Health Organization (WHO) estimates that 17.7 
million people died from a cardiovascular disease in 2015, representing 31% of all deaths 
recorded in the world. [4] In Peru, the CVD profile presented by the Pan American Health 
Organization and the WHO (PAHO/WHO) in 2014, showed that about 16% of all premature 
deaths for people between 30 and 69 years of age were due to CVD. [5] Early detection and 
prevention of CVD would help reduce the country's high mortality rate regionally. [6] 
The discovery and use of cardiovascular risk (CVR) biomarkers during the last few years has led 
to more sensitive detection methods, bringing favorable clinical outcomes in the population. 
[7] So far, dozens of CVR markers have been described, such as: Brain Natriuretic Peptide 
(BNP), Atrial Natriuretic Peptide (ANP), Troponin T, Creatinine Phosphokinase-MB, Galectin-3, 
C-Reactive Protein, Interleukin 6, Fibrinogen, Monocyte Chemotactic Protein-1, Tumor 
Necrosis Factor Alpha, Low-Density Lipoproteins, High Density Lipoprotein, Apo b-100, 
Lipoprotein-Associated Phospholipase A2, Homocysteine, Vitamin D, Fibroblast Growth Factor 
23, Adiponectin, Glycated Hemoglobin, Haptoglobin etc. [1,7–9] The detection of most of 
these biomarkers requires the development of a highly sensitive technological platform. 
Certain biomarkers of insulin resistance, such as triglycerides to glucose index (TGI) and 
triglycerides to HDL-cholesterol ratio (TG/HDL-c), have been shown to be useful in identifying 
people at high risk of developing a cardiovascular problem at an early stage. [10–12] Elevated 
plasma triglyceride levels are a CVD risk marker and are associated with impaired fasting 
glucose, type 2 diabetes, and metabolic syndrome. [13] The TG/HDL-c can help predict patients 
at increased risk of cardio metabolic disease as well as identify patients who most need 
intervention. [14,15] Likewise, the TGI has been correlated with the assessment of insulin 
resistance homeostasis model (HOMA-IR). The detection of apparently healthy individuals with 
insulin resistance (IR) before the onset of CVD could have clinical relevance in the prevention 
of cardiovascular disease. [14] Additionally, the direct measurement of these insulin resistance 
indexes does not require complex techniques, is inexpensive and can be performed in a 
routine biochemical laboratory. 
Patients with CVD usually develop three or more risk factors, so quantifying these factors is 
essential to understanding the extent of this problem. [16] Different equations and scales 
make it possible to quantify CVR, their differences being mainly due to the specific parameters 
established for the calculation. The Framingham equation estimates the risk of presenting a 
myocardial infarction: fatal or not, symptomatic or silent, and angina, assessing the risk at 10 
years. In Peru, using this score it has been shown that 20% of the population is classified with a 
high CVR with prevalence in males and in a period of 7 years this increases by 3%. [17–19] 
Recently, the QRISK model was developed, which estimates individualized lifetime CVR, 
incorporating estimates of the probability that a patient is alive and free of CVD for any age up 
to 95 years, taking into account individual risk factors, recommended for young adult 
populations. [20] In the present study, we explored the diagnostic accuracy of TG/HDL-c and 
TGI to lifetime CVR in adults from a Peruvian hospital. 
Methods 
Design of the primary study 
We conducted a cross-sectional analytical study using data from the Plan for the Prevention 
and Surveillance of Communicable and Non-Communicable Diseases at the Hospital de 
Huaycan II-1, Lima, Peru, in 2019. In this prevention plan, clinical evaluation, self-reported 
questionnaires, medical images and laboratory tests were performed to prevent and diagnose 
diseases in healthcare workers. Workers were explained that their medical data would be used 
for future research, and written informed consent was obtained from all participants.  
This study was approved by the Ethics Committee of the Universidad Peruana Union (2020-
CEUPeU-00021) and authorized by the Hospital de Huaycan (031-2020) to use medical records 
from health workers. 
Inclusion and Exclusion Criteria 
We included data of healthcare workers between 20 to 79 years old of both sexes from the 
Hospital de Huaycan. Participants with a medical record of myocardial infarction, coronary 
artery disease, cerebrovascular disease, peripheral arterial disease, as well as those who used 
antihyperlipidemic agents, pregnant women, participants who did not completely fill out the 
form, those who did not sign informed consent and those who did not do laboratory tests 
were excluded. 
Assessment of Cardiovascular Risk 
The American College of Cardiology/American Heart Association (ACC/AHA) risk score was 
calculated to measure general CVR over 10 years. [21] This score presented the best 
discrimination (AUC = 0.78) of general CVR in a Latin American population. [22] The population 
was categorized as low, borderline, intermediate, and high risk according to the ACC/AHA 2019 
guideline on the primary care of cardiovascular diseases. [23] 
The QRISK model was used to measure the lifetime-CVD [20] in low, borderline and 
intermediate risk populations based on ACC/AHA risk score, using the QRISK® on-line calculator 
(https://qrisk.org/lifetime/index.php). 
Definition of Variables   
Lifetime CVR was categorized into high (≥ 39%) and low (< 39%) risk. [24] Diabetes was defined 
as, diagnosed by doctor, currently taking anti-diabetic medication, fasting plasma glucose ≥126 
mg/dL or HbA1c ≥ 6.5%. Body mass index was categorized as underweight (<18.5 Kg/m2), 
normal (18.5 - 24.9 Kg/m2), overweight (25 - 29.9 Kg/m2) and obese (>30 Kg/m2). Smoker, 
antihypertensive medication and alcohol consumption were assessed based on self-reported 
questionnaires from the Plan for the Prevention and Surveillance of Communicable and Non-
Communicable Diseases at the Hospital de Huaycan. 
TG/HDL-c and TGI were selected as insulin resistance indexes because they have been shown 
to be accurate indicators of insulin resistance diagnosis in many populations. [15,25] 
Additionally, these insulin indexes present accessible alternatives to HOMA-IR or glucose 
clamp. [26,27] TG/HDL-c was calculated using the following formula: fasting TG (mg/dL) ÷ 
fasting HDL-cholesterol (mg/dL), and categorized into tertiles Q1 (0.56 - 2.14), Q2 (2.15 - 3.45) 
and Q3 (3.46 - 12.30). TGI was calculated using the formula: Ln[fasting TG (mg/dL) × fasting 
plasma glucose (mg/dL)/2], and categorized into tertiles Q1 (6.77 - 8.44), Q2 (8.45 - 8.94) and 
Q3 (8.95 - 11.20).  
Statistical Analysis  
Statistical analyses were performed with R program version 4.0.2. Numerical variables were 
described with mean and standard deviation. Categorical variables were described in absolute 
and relative frequencies. To assess the association between insulin resistance indexes 
(TG/HDL-c and TGI) and lifetime CVR, prevalence ratios (PR) and their respective 95% 
confidence intervals (95% CI) were determined using Poisson regression models with robust 
variance. The first model examined the bivariate association between insulin resistance 
indexes and lifetime CVR. The second model of TG/HDL-c was adjusted for sex, HbA1c, LDL-c, 
uric acid, BMI and alcohol consumption. The second model of TGI was adjusted for sex, LDL-c, 
uric acid, BMI and alcohol consumption. Receiver operating characteristic (ROC) curve analysis 
was applied to estimate the accuracy of insulin resistance indexes to lifetime CVR with the 
calculation of the area under the curve (AUC) with 95% CI. The optimal cutoff value of each 
marker was estimated using the Youden index. A p value <0.05 was considered statistically 
significant. 
Results 
General characteristics of the Participants  
We analyzed data from 291 health workers, 84 men (28.9%) and 207 women (71.1%) with an 
average age of 46 ± 10 years old. Most of the variables of the overall population presented in 
Table 1 showed average values in normal ranges. Overall, 49.1% of the health workers were 
overweight, 27.1% obese, 92.8% had low-moderate alcohol consumption, 13.1% had diabetes 
and 4.8% were smokers.  
Characteristics of the participants by lifetime cardiovascular risk 
The study population was categorized into high (n = 67) and low (n = 224) lifetime CVR. Most 
of the variables showed statistically significant differences (p < 0.01) between high and low 
lifetime CVR groups (table 1). Laboratory markers and lipid profile for the high lifetime CVR 
group showed abnormal values, only uric acid was in the normal interval in both groups. 
 
Table 1: General characteristics of the participants 
  Lifetime Cardiovascular risk  
Variables Overall (n=291) High (n =67) Low (n =224) P - value 
Sexa     
Men     84 (28.9)      38 (57.6)      46 (20.4)  <0.001* 
Women    207 (71.1)      29 (43.3)     178 (79.5)   
Age (years)  46 ± 10  49 ± 9  45 ± 10 0.003* 
Weight (Kg) 67.8 ± 13.0 78.4 ± 14.2 64.7 ± 10.7 <0.001* 
SBP (mmHg) 108 ± 13 116 ± 12 106 ± 12 <0.001* 
DBP (mmHg) 69 ± 10 74 ± 11 67 ± 10 <0.001* 
Glucose (mg/dL) 95.9 ± 32.8 115.5 ± 60.9 90.0 ± 12.3 <0.001* 
HbA1c (%) 6.02 ± 1.03 6.64 ± 1.69 5.84 ± 0.61 <0.001* 
Cholesterol (mg/dL) 192.9 ± 36.7 216.7 ± 37.3 185.8 ± 33.4 <0.001* 
LDL-c (mg/dL) 114.6 ± 30.2 134.4 ± 33.8 108.3 ± 26.0 <0.001* 
VLDL-c (mg/dL) 28.7 ± 12.7 35.8 ± 11.9 26.6 ± 12.2 <0.001* 
HDL-c (mg/dL) 49.9 ± 10.3 46.4 ± 9.3 51.0 ± 10.4 0.001* 
Triglycerides (mg/dL) 151.1 ± 77.5 201.6 ± 87.0 136.0 ± 67.6 <0.001* 
Col/HDL-c  3.99 ± 1.03 4.79 ± 0.97 3.75 ± 0.93 <0.001* 
TG/HDL-c  3.20 ± 1.91 4.50 ± 2.07 2.82 ± 1.68 <0.001* 
TGI  8.74 ± 0.58 9.19 ± 0.61 8.60 ± 0.49 <0.001* 
Uric acid (mg/dL) 3.8 ± 1.0 4.3 ± 1.0 3.7 ± 1.0 <0.001* 
Smokera     
Yes 14 (4.8) 6 (9.0) 8 (3.6) 0.139 
No   277 (95.2)   61 (91.0)   216 (96.4)  
Diabetesa     
Yes 38 (13.1) 31 (46.3) 7 (3.1) <0.001* 
No   253 (86.9)   36 (53.7)   217 (96.9)  
BMIa     
Normal     69 (23.7)       5 (7.5)      64 (28.6)  <0.001* 
Overweight    143 (49.1)      27 (40.3)     116 (51.8)   
Obesity     79 (27.1)      35 (52.2)      44 (19.6)   
Alcohol consumptiona     
Low-moderate    270 (92.8)      62 (92.5)     208 (92.9)  1 
High     21 (7.2)       5 (7.5)      16 (7.1)   
Data expressed as mean ± standard deviation or number (%). BMI, Body mass index; LDL-c, Low density 
lipoprotein cholesterol; HDL-c, High density lipoprotein cholesterol; VLDL-c, Very low density lipoprotein 
cholesterol; Col/HDL, Total Cholesterol to HDL-cholesterol ratio; TG/HDL, Triglycerides to HDL-
cholesterol ratio; TGI, Triglycerides Glucose index; HbA1c, Glycosylated hemoglobin; SBP, Systolic blood 
pressure; DBP, Diastolic blood pressure. aWeighted percentage, *p<0.01 
 
Association of insulin resistance indexes and lifetime cardiovascular risk 
All regression models were performed with Poisson regression analysis to determine the 
association between insulin resistance indexes and lifetime CVR (Table 2). The non-adjusted 
model for tertiles of TG/HDL-c showed more prevalence of high lifetime CVR in Q2 (PR = 2.62, 
95%CI: 1.10 - 6.28, p = 0.03) and Q3 (PR = 6.06, 95%CI: 2.72 - 13.49, p<0.001) compared to Q1. 
Similarly, tertil Q2 (PR = 5, 95%CI: 1.70 - 14.70, p = 0.003) and Q3 (PR = 11.46, 95%CI: 4.12 - 
31.89, p<0.001) of TGI showed more prevalence of lifetime CVR compared to Q1. 
 
The adjusted model for tertiles of TG/HDL-c showed high prevalence of lifetime CVR in Q3 (PRa 
= 2.72, 95%CI: 1.13 - 6.57, p = 0.026) compared to Q1. TGI presented more prevalence of 
lifetime CVR in Q2 (PRa = 3.08, 95%CI: 1.01 - 9.41, p = 0.048) and Q3 (PRa = 4.73, 95%CI: 1.56 - 
14.31, p = 0.006) tertiles compared to Q1. The association of TGI was stronger than TG/HDL-c 
in all regression models.   
 
Table 2: Prevalence ratio and 95% CIs for Lifetime cardiovascular risk according to insulin resistance 
indexes tertiles. 
 Insulin resistance index tertiles 
Markers Q1 Q2 p-value Q3 p-value 
 PR PR (95% CI)  PR (95% CI)  
TG/HDL-c      
Model 1a 1 2.62 (1.10 - 6.28) 0.030* 6.06 (2.72 – 13.49) <0.001** 
Model 2b 1 1.51 (0.60 – 3.78) 0.382 2.72 (1.13 – 6.57) 0.026*     
TGI      
Model 1a 1 5.00 (1.70 – 14.70) 0.003** 11.46 (4.12 - 31.89) <0.001** 
Model 2c 1 3.08 (1.01 – 9.41) 0.048* 4.73 (1.56 - 14.31) 0.006** 
Q1, Low tertile; Q2, Middle tertile; Q3, high tertile; CI, Confidence interval; PR, Prevalence ratio; 
TG/HDL-c, Triglycerides to HDL-cholesterol ratio; TGI, Triglycerides Glucose index. aNon adjusted; 
bAdjusted for Sex, HbA1c, LDL-c, Uric acid, BMI and alcohol consumption; cAdjusted for Sex, LDL-c, Uric 
acid, BMI and alcohol consumption; *p<0.05; **p<0.01. 
 
Diagnostic accuracy of insulin resistance indexes  
The ROC analysis of insulin resistance indexes and lifetime CVR overall showed that the AUC of 
TG/HDL-c was 0.77 (sensitivity: 0.86, specificity: 0.60) while the TGI AUC was 0.80 (sensitivity: 
0.64, specificity: 0.83). TG/HDL-c in men presented an AUC of 0.80 (sensitivity: 0.66, specificity: 
0.87) while their TGI AUC was 0.79 (sensitivity: 0.69, specificity: 0.80). TG/HDL-c in women 
showed an AUC of 0.74 (sensitivity: 0.86, specificity: 0.60) while their TGI AUC was 0.80 
(sensitivity: 0.66, specificity: 0.82) (Figure 1). Each marker presented good diagnostic accuracy 
to high lifetime CVR in men, women and overall. The optimal cut off point of each marker to 
predict high lifetime CVR is presented in table 3. 
 
Table 3: Diagnostic accuracy of TG/HDL-col and TGI in predicting Lifetime cardiovascular 
risk and their optimal cut-off values 
Predictors  Overall Men Women 
Value (CI 95%) Value (CI 95%) Value (CI 95%) 
TG/HDL-c    
Optimal Cut-off 2.64 3.90 2.64 
AUC  0.77 (0.71 – 0.83) 0.80 (0.70 – 0.90) 0.74 (0.65 – 0.83) 
Sensitivity  0.86 (0.76 – 0.94) 0.66 (0.49 – 0.80) 0.86 (0.68 – 0.96) 
Specificity  0.60 (0.54 – 0.67) 0.87 (0.74 – 0.95) 0.60 (0.52 – 0.67) 
PPV  0.39 (0.33 – 0.60) 0.81 (0.64 – 0.90) 0.26 (0.20 – 0.58) 
NPV  0.94 (0.88 – 0.95) 0.75 (0.60 – 0.90) 0.96 (0.90 – 0.97) 
TGI    
Optimal Cut-off 9.04 8.95 9.04 
AUC  0.80 (0.74 – 0.86) 0.79 (0.69 – 0.89) 0.80 (0.72 – 0.88) 
Sensitivity  0.64 (0.51 – 0.76) 0.68 (0.51 – 0.82) 0.66 (0.46 – 0.82) 
Specificity  0.83 (0.77 – 0.88) 0.80 (0.66 – 0.91) 0.82 (0.76 – 0.88) 
PPV  0.53 (0.44 – 0.66) 0.74 (0.58 – 0.86) 0.38 (0.29 – 0.60) 
NPV  0.88 (0.82 – 0.92) 0.76 (0.60 – 0.88) 0.94 (0.87 – 0.96) 
 AUC, Area under the curve; TG/HDL-c, Triglycerides to HDL-cholesterol ratio; TGI, 
Triglycerides Glucose index; PPV, positive predictive value; NPV, negative predictive 
value. 
 
Figure 1: ROC curve of TG/HDL-c and TGI for predicting Lifetime cardiovascular risk. (a) Overall (Cut-offs, 
TG/HDL-c: 2.64; TGI: 9.04), (b) Men (Cut-offs, TG/HDL-c: 3.90; TGI: 8.95), (c) women (Cut-offs, TG/HDL-c: 
2.64; TGI: 9.04). 
Discussion 
The identification of seemingly healthy people with insulin resistance before the manifestation 
of cardiovascular diseases is an important step in the prevention of cardiovascular events. 
Several studies widely use TG/HDL-col and TGI indices as markers of insulin resistance.[26,28–
30] Recent studies mention that these indexes could be useful to identify people at high risk of 
developing some cardiovascular event early. [14,15,31–33] In the present study, TG/HDL-c and 
TGI indices presented independent association to lifetime CVR and good diagnostic accuracy. 
To our knowledge this is the first study to assess the association of insulin indexes to lifetime 
CVR in a Peruvian population. 
 
Several studies showed that TG/HDL-c is a risk factor for global cardiovascular mortality [25] , 
calcification of arteries [34] and coronary artery disease [35] in adult and young population. 
[11,36] For example, a study in adults from the U.S. found that high TG/HDL-c (>2.5 in women 
or >3.5 in men) increased by 1.5 times the incidence of type 2 diabetes and CVD [14]. Another 
study showed that high TG/HDL-c increased by 2 times the incidence of events and mortality 
due to CVD in nondiabetic dialysis patient from Taiwan [37] and in obese type 2 diabetes 
patients TG/HDL-c ≥ 1.9 presented a 1.6 time increase in the risk of CVD compared with 
normal weight patients. [36] In this study, the TG/HDL-c ratio increases by 2.72 times the 
lifetime CVR, according to the adjusted model. The relationship could be explained through 
increased insulin resistance when TG/HDL-c is high. [25] Additionally, the cutoff values for CVR 
in our study were similar to other studies [38] but cutoff values for insulin resistance differ 
from cardiovascular risk [27]. This could be because insulin resistance is the beginning of 
metabolic changes that predispose many cardiometabolic diseases. [39]   
 
TGI is a surrogate marker of insulin resistance that in different studies was proposed as a 
predictor of cardiovascular disease. [40] Likewise, a study in patients from Taiwan showed that 
high levels of TGI increased by 1.5 times the risk of CVD [9]. Another study from Spain found 
that high levels of TGI increased by 2 times the incidence of CVD in adults and the ROC models 
integrating TGI were better than Framingham model. [15] In the same way, a study in children 
and adolescents with normal weight from Mexico showed that the high quintile of TGI was 
associated with hypertriglyceridemia, hyperglycemia and low HDL-c. [41] We found that the 
TGI index significantly increases, by 4.73 times, the lifetime CVR, following the adjusted model. 
The cutoff values of TGI in our study were higher than other populations [41], this fact can be 
explained through lifestyle and eating habits in Peru which are mainly carbohydrates-based. 
[42] 
 
Both TG/HDL-c and TGI presented a good AUC for lifetime CVR in our study. Likewise, studies 
in Asian population showed that the cutoff value of TGI was between 8 to 9 with an AUC of 0.6 
to 0.8 for predicting cardiovascular events. [15,40,43] Another study in a Japanese population 
determined the optimal cutoff values for TG/HDL-c were 2.9 for men and 2.3 for women with 
an AUC of 0.8 for predicting cardiometabolic risk. [44] However, a population from China 
reported TG/HDL-c cutoff values of 1.4 for men and 1.0 for women for predicting elevated CVR 
factors. [45] It is important to determine the optimal cutoff for TGI and TG/HDL-c for 
predicting cardiovascular events in a Latin American population. 
 
Insulin resistance is a metabolic state that leads to many cardiometabolic diseases. [39] This is 
caused through defects in the metabolic pathway of insulin receptors, mammalian target of 
rapamycin (mTOR) and ribosomal protein S6 kinase beta 1 (S6K1) with an increase of 
proinflammatory proteins, endothelial dysfunction, renin-angiotensin system and dyslipidemia 
[45] Additionally, this metabolic state is related to cultural lifestyle factors such as nutrition 
and physical activity. [17] In our study, we found adults with normal traditional metabolic 
markers (table 1) but with high lifetime CVR, this fact highlights the necessity of new markers 
in medical practice and primary prevention in cardiovascular health.     
 
The prediction of lifetime CVR in developing countries such as Peru is very important given all 
the consequences of CVD in the population and the healthcare system. TG/HDL-c and TGI are 
inexpensive and accessible markers. In this way, they could aid in the assessment of CVR and 
establish therapeutic goals in primary prevention care. 
 
This study presents some limitations, notably that it was carried out in health workers from a 
hospital from Peru and cannot be generalized for the general population. It was not possible to 
assess causality of variables due to the nature of the cross-sectional study design used. The 
findings are also limited by the absence of assessment for hypothyroidism, renal and liver 
diseases. However, no endocrine, renal or liver pathologies were registered in the workers’ 
medical records. In this study, the analysis was adjusted by potential confounders; however, 
future studies must consider these limitations and include more lifestyle factors.  
Conclusions 
In conclusion, the TG/HDL-c and TGI showed significant independent association to lifetime 
CVR after adjusted potential confounders in adults in the healthcare sector from Peru. The 
association of TGI was stronger than TG/HDL-c in this study. Likewise, diagnostic accuracy of 
both markers was good in men, women and overall population. These indexes could be 
practical and reliable markers for CVR and useful tools in primary prevention programs for 
cardiovascular health. 
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